1443377-33-0 → HCID 71737065, compound

HRID 2172329Notes

Reaction equation

HRID 2172329 reaction equation
[CH:1]1([C:4]2[CH:9]=[CH:8][C:7](B3OC(C)(C)C(C)(C)O3)=[C:6]([O:19][CH3:20])[CH:5]=2)[CH2:3][CH2:2]1.Cl[C:22]1[N:31]=[CH:30][CH:29]=[C:28]2[C:23]=1[CH2:24][CH2:25][N:26]([S:32]([NH:35][C:36]1[S:40][N:39]=[CH:38][N:37]=1)(=[O:34])=[O:33])[CH2:27]2>>[CH:1]1([C:4]2[CH:9]=[CH:8][C:7]([C:22]3[N:31]=[CH:30][CH:29]=[C:28]4[C:23]=3[CH2:24][CH2:25][N:26]([S:32]([NH:35][C:36]3[S:40][N:39]=[CH:38][N:37]=3)(=[O:34])=[O:33])[CH2:27]4)=[C:6]([O:19][CH3:20])[CH:5]=2)[CH2:2][CH2:3]1

Participants

3

Reactant 2

HCID 665215481443377-33-02×HCID 89815259HCID 89815259, compound2×

Product 1

HCID 71737065HCID 71737065, compound

Procedure

The title compound was prepared in a manner analogous to Example 1, except that 2-(4-cyclopropyl-2-methoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (Intermediate W) was used in place of (2-(1-methyl-1H-pyrazol-5-yl)-4-(trifluoromethyl)phenyl)boronic acid and 5-chloro-N-(1,2,4-thiadiazol-5-yl)-3,4-dihydro-2,6-naphthyridine-2(1H)-sulfonamide (Intermediate V) was used in place of 5-bromo-N-(1,2,4-thiadiazol-5-yl)-3,4-dihydroisoquinoline-2(1H)-sulfonamide. [M+H]+=444.0 1H NMR (400 MHz, Acetone-d6) δ ppm: 8.35 (d, J=5.0 Hz, 1H), 8.12-8.17 (m, 1H), 7.10 (d, J=5.1 Hz, 1H), 7.05 (d, J=7.8 Hz, 1H), 6.82 (d, J=1.6 Hz, 1H), 6.74 (d, J=7.7 Hz, 1H), 4.28-4.43 (m, 2H), 3.76 (s, 3H), 3.43-3.56 (m, 1H), 2.79-3.22 (br. m, 2H), 2.38-2.52 (br. m, 1H), 1.94-2.02 (m, 1H), 0.93-1.03 (m, 2H), 0.71-0.81 (m, 2H)

Sources & evidence

ORD record
ord-827cdf36bb84483490d56666c477dfe8
Source dataset
uspto-grants-2015_06
Patent number
US09051311B2

Reaction notes

Loading…